Pharmacokinetic interaction between epirubicin and the multidrug resistance reverting agent D-verapamil.

The potential for a pharmacokinetic interaction between epirubicin and the second-generation multidrug resistance modulating agent D-verapamil (DVPM) has been investigated in six patients with advanced colorectal cancer. Our results indicate that a significant interaction takes place. Enhanced distr...

Descripción completa

Detalles Bibliográficos
Autores principales: Scheithauer, W., Schenk, T., Czejka, M.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1993
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968306/
https://www.ncbi.nlm.nih.gov/pubmed/8318424
_version_ 1782134711388209152
author Scheithauer, W.
Schenk, T.
Czejka, M.
author_facet Scheithauer, W.
Schenk, T.
Czejka, M.
author_sort Scheithauer, W.
collection PubMed
description The potential for a pharmacokinetic interaction between epirubicin and the second-generation multidrug resistance modulating agent D-verapamil (DVPM) has been investigated in six patients with advanced colorectal cancer. Our results indicate that a significant interaction takes place. Enhanced distribution of epirubicin from the serum and altered disposition might, in fact, explain the increased level of myelotoxicity in this pilot as well as in other clinical phase II studies involving DVPM.
format Text
id pubmed-1968306
institution National Center for Biotechnology Information
language English
publishDate 1993
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19683062009-09-10 Pharmacokinetic interaction between epirubicin and the multidrug resistance reverting agent D-verapamil. Scheithauer, W. Schenk, T. Czejka, M. Br J Cancer Research Article The potential for a pharmacokinetic interaction between epirubicin and the second-generation multidrug resistance modulating agent D-verapamil (DVPM) has been investigated in six patients with advanced colorectal cancer. Our results indicate that a significant interaction takes place. Enhanced distribution of epirubicin from the serum and altered disposition might, in fact, explain the increased level of myelotoxicity in this pilot as well as in other clinical phase II studies involving DVPM. Nature Publishing Group 1993-07 /pmc/articles/PMC1968306/ /pubmed/8318424 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Scheithauer, W.
Schenk, T.
Czejka, M.
Pharmacokinetic interaction between epirubicin and the multidrug resistance reverting agent D-verapamil.
title Pharmacokinetic interaction between epirubicin and the multidrug resistance reverting agent D-verapamil.
title_full Pharmacokinetic interaction between epirubicin and the multidrug resistance reverting agent D-verapamil.
title_fullStr Pharmacokinetic interaction between epirubicin and the multidrug resistance reverting agent D-verapamil.
title_full_unstemmed Pharmacokinetic interaction between epirubicin and the multidrug resistance reverting agent D-verapamil.
title_short Pharmacokinetic interaction between epirubicin and the multidrug resistance reverting agent D-verapamil.
title_sort pharmacokinetic interaction between epirubicin and the multidrug resistance reverting agent d-verapamil.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968306/
https://www.ncbi.nlm.nih.gov/pubmed/8318424
work_keys_str_mv AT scheithauerw pharmacokineticinteractionbetweenepirubicinandthemultidrugresistancerevertingagentdverapamil
AT schenkt pharmacokineticinteractionbetweenepirubicinandthemultidrugresistancerevertingagentdverapamil
AT czejkam pharmacokineticinteractionbetweenepirubicinandthemultidrugresistancerevertingagentdverapamil

Ejemplares similares